Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10130)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
PML
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Responsed Disease | Ovarian cancer | ICD-11: 2C73 | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Gluconeogenesis | hsa00010 | ||||
Oxidative phosphorylation | hsa00190 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
SK-OV-3 cells | Ovarian serous cystadenocarcinoma | Homo sapiens | CVCL_0532 | |
OV-90 cells | Ovarian adenocarcinoma | Homo sapiens | CVCL_3768 | ||
Caov-3 cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_0201 | ||
OV7 cells | Ovarian carcinoma | Homo sapiens | CVCL_2675 | ||
COV504 cells | Ovarian carcinoma | Homo sapiens | CVCL_2424 | ||
OV56 cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_2673 | ||
OVCAR-8 cells | High grade ovarian serous adenocarcinoma | Homo sapiens | CVCL_1629 | ||
OC 314 cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_1616 | ||
KURAMOCHI cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_1345 | ||
OVSAHO cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_3114 | ||
OVCAR-4 cells | Ovarian adenocarcinoma | Homo sapiens | CVCL_1627 | ||
FU-OV-1 cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_2047 | ||
COV318 cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_2419 | ||
In Vivo Model |
Tumor fragments from PDX models were grafted into the interscapular fat pad of 6-week-old female Swiss nude mice under avertin anesthesia. When tumors reached a volume of 60-200 mm3, mice were blindly assigned to control (vehicle, NaCl 0.9%) or treated groups (at least n = 9 per condition). Mice were treated intraperitoneally by carboplatin (ACCORD) at 66 mg / kg every three weeks and paclitaxel (KABI) at 12 mg / kg once a week.
Click to Show/Hide
|
||||
Response regulation | In high-OXPHOS tumors, chronic oxidative stress promotes aggregation of PML-nuclear bodies, resulting in activation of the transcriptional co-activator PGC-1. Active PGC-1 increases synthesis of electron transport chain complexes, thereby promoting mitochondrial respiration. The data establish a stress-mediated PML-PGC-1-dependent mechanism that promotes OXPHOS metabolism and chemosensitivity in ovarian cancer. | ||||
Ovarian cancer [ICD-11: 2C73]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | ||||
Target Regulator | Protein PML (PML) | Protein coding | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Gluconeogenesis | hsa00010 | ||||
Oxidative phosphorylation | hsa00190 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
SK-OV-3 cells | Ovarian serous cystadenocarcinoma | Homo sapiens | CVCL_0532 | |
OV-90 cells | Ovarian adenocarcinoma | Homo sapiens | CVCL_3768 | ||
Caov-3 cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_0201 | ||
OV7 cells | Ovarian carcinoma | Homo sapiens | CVCL_2675 | ||
COV504 cells | Ovarian carcinoma | Homo sapiens | CVCL_2424 | ||
OV56 cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_2673 | ||
OVCAR-8 cells | High grade ovarian serous adenocarcinoma | Homo sapiens | CVCL_1629 | ||
OC 314 cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_1616 | ||
KURAMOCHI cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_1345 | ||
OVSAHO cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_3114 | ||
OVCAR-4 cells | Ovarian adenocarcinoma | Homo sapiens | CVCL_1627 | ||
FU-OV-1 cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_2047 | ||
COV318 cells | Ovarian serous adenocarcinoma | Homo sapiens | CVCL_2419 | ||
In Vivo Model |
Tumor fragments from PDX models were grafted into the interscapular fat pad of 6-week-old female Swiss nude mice under avertin anesthesia. When tumors reached a volume of 60-200 mm3, mice were blindly assigned to control (vehicle, NaCl 0.9%) or treated groups (at least n = 9 per condition). Mice were treated intraperitoneally by carboplatin (ACCORD) at 66 mg / kg every three weeks and paclitaxel (KABI) at 12 mg / kg once a week.
Click to Show/Hide
|
||||
Response regulation | In high-OXPHOS tumors, chronic oxidative stress promotes aggregation of PML-nuclear bodies, resulting in activation of the transcriptional co-activator PGC-1. Active PGC-1 increases synthesis of electron transport chain complexes, thereby promoting mitochondrial respiration. The data establish a stress-mediated PML-PGC-1-dependent mechanism that promotes OXPHOS metabolism and chemosensitivity in ovarian cancer. | ||||